[1] Torres-Durán M, Lopez-Campos JL, Barrecheguren M, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis,2018,13:114.
[2] Wang L, Marek GW, Hlady RA, et al. Alpha-1 antitrypsin deficiency liver disease, mutational homogeneity modulated by epigenetic heterogeneity with links to obesity. Hepatology ,2019,70:51-66.
[3] Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. Am J Respir Crit Care Med,2012,185:373-381.
[4] Esquinas C, Janciauskiene S, Gonzalo R, et al. Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis,2017,12:3381-3390.
[5] Hassan T, Carroll TP, Buckley PG, et al. miR-199a-5p silencing regulates the unfolded protein response in chronic obstructive pulmonary disease and α1-antitrypsin deficiency. Am J Respir Crit Care Med,2014,189:263-273.
[6] Bouchecareilh M, Hutt DM, Szajner P, et al. Histone deace-tylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA)-mediated correction of α1-antitrypsin deficiency. J Biol Chem,2012,287:38265-38278.
[7] Di Bisceglie AM, Teckman J. Liver disease due to alpha-1 anti-trypsin deficiency: Are we surprised that it is more complex than we thought? Hepatology,2019,70:5-7. |
